PCM
ARCT icon

Potomac Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Potomac Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,243
Closed -$242K – 75
2014
Q3 		$242K Buy
+2,243
New +$292K 0.26% 64

Other funds holding ARCT

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Potomac Capital Management's ARCT Position: Q4 2014 in Review

Potomac Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2014, closing a stake of 2,243 shares — an estimated $242K sold.

Potomac Capital Management first reported a position in ARCT in Q3 2014 and held it in 1 quarter. The position peaked at $242K in Q3 2014. 28 funds tracked by Wall St. Rank hold ARCT as of Q4 2014.

  • Potomac Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Potomac Capital Management sold 2,243 Arcturus Therapeutics shares in Q4 2014, an estimated $242K.
  • Potomac Capital Management first reported a position in Arcturus Therapeutics in Q3 2014 and held it in 1 quarter.
  • Potomac Capital Management's Arcturus Therapeutics position peaked at $242K in Q3 2014.
  • 28 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2014.

Based on Potomac Capital Management's 13F filing for Q4 2014, filed 11 Feb 2015.